Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
62,337,402
-
Total 13F shares
-
14,278,057
-
Share change
-
-1,091,078
-
Total reported value
-
$16,133,000
-
Price per share
-
$1.13
-
Number of holders
-
20
-
Value change
-
-$1,528,405
-
Number of buys
-
5
-
Number of sells
-
9
Institutional Holders of Elevation Oncology, Inc. - Common stock, par value $0.0001 per share (ELEV) as of Q3 2022
As of 30 Sep 2022,
Elevation Oncology, Inc. - Common stock, par value $0.0001 per share (ELEV) was held by
20 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
14,278,057 shares.
The largest 10 holders included
Aisling Capital Management LP, Qiming U.S. Ventures Management, LLC, BVF INC/IL, Cormorant Asset Management, LP, venBio Partners LLC, Samsara BioCapital, LLC, TCG Crossover Management, LLC, Sio Capital Management, LLC, VANGUARD GROUP INC, and RENAISSANCE TECHNOLOGIES LLC.
This page lists
20
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.